SCHEMBL4568366

SCHEMBL4568366

COc1ccc(CC(=O)c2cncc(F)c2)c(NC(=O)OC(C)(C)C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.37
CYP17A1 P05093 1/20 0.37
KCNQ4 P56696 1/20 0.36
KCNQ5 Q9NR82 1/20 0.36
EPHX2 P34913 1/20 0.36
ABL1 P00519 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35
ANO1 Q5XXA6 1/20 0.35
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
NR1I2 O75469 1/20 0.35
TP53 P04637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
USP2 O75604 1/20 0.34
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568368 0.91 DYRK1A (0.39) DYRK1ACYP17A1SMN1; SMN2POLBTSHR
SCHEMBL4568054 0.86 SMN1; SMN2 (0.47) KCNQ4KCNQ5EPHX2SMN1; SMN2TSHR
SCHEMBL4568049 0.86 RAB9A (0.46) SMN1; SMN2POLBTSHRANO1KDM4E
SCHEMBL4568053 0.85 TSHR (0.49) SMN1; SMN2POLBTSHRKDM4EMEN1
SCHEMBL4568360 0.84 MAPT (0.36) KCNQ4KCNQ5EPHX2SMN1; SMN2ANO1
SCHEMBL4568362 0.83 CYP17A1 (0.37) CYP17A1EPHX2SMN1; SMN2POLBANO1
SCHEMBL4568358 0.82 GAA (0.42) CYP17A1EPHX2SMN1; SMN2TP53MEN1
SCHEMBL4568012 0.82 KMT2A (0.45) EPHX2SMN1; SMN2POLBANO1TP53
SCHEMBL4568067 0.81 KMT2A (0.50) SMN1; SMN2POLBANO1TP53KDM4E
SCHEMBL4568052 0.81 NPC1 (0.46) SMN1; SMN2TSHRTP53MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R DYRK1A 920/4885CYP17A1 1315/4885KCNQ4 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.